Enlivex (ENLV) vs Imunon (IMNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Imunon is the larger company by market cap ($5.7 million vs $5.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | IMNN |
|---|---|---|
| Share price | $0.2686 | $1.02 |
| Market cap | $5.35M | $5.72M |
| 1-day change | -3.03% | -4.63% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $5.39 |
| 52-week low | $0.224 | $0.96 |
| Distance from 52-week high | -99.01% | -81.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +29684.07% | +1566.67% |
| Average volume | 945.30K | 155.30K |
| Shares outstanding | 19.91M | 5.61M |
| Employees | 34 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
ENLV vs IMNN FAQ
Which is bigger, Enlivex or Imunon?
Imunon (IMNN) is larger, with a market capitalization of $5.72M compared with $5.35M for Enlivex (ENLV).
Are Enlivex and Imunon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.